Compare AbbVie Inc (ABBV) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Freeport-McMoRan Inc — how do they compare? AbbVie Inc trades at $250.41 (market cap $439.59B), while Freeport-McMoRan Inc trades at $67.22 (market cap $96.91B). The key difference: AbbVie Inc is far larger — about 4.5× Freeport-McMoRan Inc's market cap, and AbbVie Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| ABBV | FCX | |
|---|---|---|
Market Cap | $439.59B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $71.73 |
52-Week Low | $197.38 | $35.34 |
Enterprise Value | $503.84B | $103.19B |
Dividend Yield | 2.78% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $250.13, up 0.08% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q2 2026 EPS of $3.65 versus $3.61 expected, highlight operational strength. Revenue growth is robust, projected to rise to $64.4B in 2026, driven by immunology drugs Skyrizi and Rinvoq offsetting Humira declines. The stock nears resistance at $252, with a consensus price target of $278.69 suggesting 11% upside.
Outlook is positive due to pipeline advancements, such as Phase 2 ovarian cancer data (PRNewsWire, April 12, 2026), and dividend reliability. Risks include patent expirations in the 2030s and high debt levels. With 71% analyst buy ratings and institutional accumulation, ABBV offers growth and income, but investors must monitor competitive and regulatory pressures.
FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.
Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
